Peters et al. [83] and Gadgeel et al. [84] independently demonstrated alectinib’s superior PFS and central nervous system (CNS) activity in untreated ALK+ NSCLC patients, irrespective of prior CNS disease. This evidence concerns the gene ALK and non-small cell lung carcinoma.